# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

> **NCT03220347** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 139 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Neoplasms

## Interventions

- **DRUG:** CC-90010

## Key facts

- **NCT ID:** NCT03220347
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-24
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220347, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03220347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*